See more : Omnipotent Industries Limited (OMNIPOTENT.BO) Income Statement Analysis – Financial Results
Complete financial analysis of PROCEPT BioRobotics Corporation (PRCT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PROCEPT BioRobotics Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Sharecare, Inc. (SHCR) Income Statement Analysis – Financial Results
- Fortune Brands Innovations, Inc. (2FB.DE) Income Statement Analysis – Financial Results
- NICE Ltd. (NICE.TA) Income Statement Analysis – Financial Results
- Big Red Mining Corp. (RED.CN) Income Statement Analysis – Financial Results
- Avingtrans plc (AVG.L) Income Statement Analysis – Financial Results
PROCEPT BioRobotics Corporation (PRCT)
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 136.19M | 75.01M | 34.47M | 7.72M | 6.17M |
| Cost of Revenue | 65.14M | 37.93M | 18.61M | 8.97M | 8.05M |
| Gross Profit | 71.05M | 37.09M | 15.87M | -1.26M | -1.89M |
| Gross Profit Ratio | 52.17% | 49.44% | 46.02% | -16.26% | -30.56% |
| Research & Development | 48.45M | 28.98M | 18.99M | 16.28M | 13.15M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 131.77M | 88.83M | 51.04M | 30.27M | 28.52M |
| Other Expenses | 0.00 | -203.00K | -154.00K | -25.00K | -46.00K |
| Operating Expenses | 180.22M | 117.81M | 70.03M | 46.55M | 41.67M |
| Cost & Expenses | 245.36M | 155.74M | 88.64M | 55.52M | 49.72M |
| Interest Income | 7.55M | 2.01M | 121.00K | 184.00K | 1.15M |
| Interest Expense | 4.00M | 5.18M | 5.81M | 5.26M | 724.00K |
| Depreciation & Amortization | 3.81M | 4.32M | 2.98M | 2.70M | 1.49M |
| EBITDA | -98.10M | -77.65M | -51.06M | -45.06M | -39.76M |
| EBITDA Ratio | -72.03% | -104.93% | -156.77% | -580.32% | -663.85% |
| Operating Income | -109.17M | -80.72M | -54.16M | -47.80M | -43.55M |
| Operating Income Ratio | -80.16% | -107.61% | -157.12% | -619.44% | -705.95% |
| Total Other Income/Expenses | 3.27M | -6.43M | -5.69M | -5.22M | 1.58M |
| Income Before Tax | -105.90M | -87.15M | -59.85M | -53.02M | -41.98M |
| Income Before Tax Ratio | -77.76% | -116.18% | -173.62% | -687.04% | -680.42% |
| Income Tax Expense | 0.00 | 6.43M | 2.53M | 5.24M | 678.00K |
| Net Income | -105.90M | -93.58M | -62.38M | -58.26M | -42.65M |
| Net Income Ratio | -77.76% | -124.76% | -180.96% | -754.89% | -691.41% |
| EPS | -2.24 | -2.11 | -1.43 | -1.35 | -0.99 |
| EPS Diluted | -2.24 | -2.11 | -1.43 | -1.35 | -0.99 |
| Weighted Avg Shares Out | 47.26M | 44.40M | 43.68M | 43.25M | 43.25M |
| Weighted Avg Shares Out (Dil) | 47.26M | 44.40M | 43.68M | 43.25M | 43.25M |
From Science Fiction to Reality: 3 Robotics Stocks for Automatic Riches
Robotics stocks should be a leading investment theme throughout the 2020s. The concept of automating factories, warehouses and data entry work has long appealed to large corporations.
PROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock Conference
SAN JOSE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the...
Real-World, Long-Term Data Demonstrate Sustained Benefits of Aquablation Therapy for Men with Benign Prostatic Hyperplasia
Data from the Icahn School of Medicine at Mount Sinai and Potomac Urology presented at the 2024 AUA Annual Meeting highlight Aquablation therapy's potential to become the new standard of care in BPH for prostates of all sizes Data from...
PROCEPT BioRobotics Corporation (PRCT) Q1 2024 Earnings Call Transcript
PROCEPT BioRobotics Corporation (NASDAQ:PRCT ) Q1 2024 Earnings Conference Call May 1, 2024 9:00 AM ET Company Participants Matt Basco - Vice President, Investor Relations Reza Zadno - Chief Executive Officer Sham Shiblaq - Chief Commercial Officer Kevin Waters -...
Biotech Leader Procept BioRobotics Jumps Past Buy Point On Earnings
Procept Stock: Biotech leader Procept BioRobotics is breaking out past its latest buy point. Shares jumped on Q1 earnings results Wednesday.
PROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue Estimates
PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.63 per share a year ago.
PROCEPT BioRobotics Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
SAN JOSE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended...
PROCEPT BioRobotics Announces 12 Scientific Research Presentations on Aquablation Therapy for the Treatment of Benign Prostatic Hyperplasia at the 2024 AUA Annual Meeting
Presentations include first published experience report of same-day discharge in an ambulatory surgical center, real-world data outcomes and 5-year data comparison between two FDA trials Presentations include first published experience report of same-day discharge in an ambulatory surgical center, real-world...
PROCEPT BioRobotics Corp. Announces Investor Event at 2024 AUA Annual Meeting in San Antonio, Texas
SAN JOSE, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today it will host an in-person investor event on Friday, May...
PROCEPT BioRobotics to Report First Quarter 2024 Financial Results on May 1, 2024 and Attend the 2024 Bank of America Healthcare Conference on May 15, 2024
SAN JOSE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the...
Source: https://incomestatements.info
Category: Stock Reports